A new study links a variant of the apolipoprotein E gene called APOE ε4 to better memory in older age, even in the presence of amyloid plaques—a possible explanation for the variant’s persistence despite its association with an increased risk of Alzheimer’s disease.

Pharmaceutical companies ramp up efforts to get the brain’s immune cells to help treat Alzheimer’s disease and other conditions, but not everyone agrees the approach will be effective.

A lackluster performance in clinical trials of the monoclonal antibody aducanumab has left some experts unconvinced of its benefit.

A dysfunctional lymphatic system, described as a clogging of the brain’s sink, may explain why immunotherapies fail in some Alzheimer’s patients.

The test will be a cheaper and more accessible alternative to currently available diagnostic tools, researchers say.

These “coarse-grained” plaques resemble those that clog up the brain’s blood vessels in a different disease, pointing to links between the vascular system and the neurodegenerative disease.

Accumulation of the protein was more likely to be found in the brains of people who slept less well years earlier, according to a new study.

New studies show that elevated levels of a form of tau called p-tau217 can accurately distinguish Alzheimer’s disease from other forms of dementia, and perhaps even predict it.

The widely expected move comes months after the companies scrapped trials of another Alzheimer’s drug.

Exposing mice to an hour of 40-hertz stimuli every day for a week reduced levels of amyloid-β plaques and tau protein, and improved cognition.

The test uses levels of plasma amyloid-β to estimate the buildup of protein plaques in the brain.

The once fringe idea is gaining traction among the scientific community.

Emerging evidence links bacterial or viral infection with the neuropathology of Alzheimer’s disease.

In a mouse model, researchers mitigated three Alzheimer’s disease–associated symptoms by stimulating gamma waves with light.

Mineral nanoparticles similar to those that have been associated with Alzheimer’s disease may enter the brain through the inhalation of polluted air.

Biogen’s aducanumab reduces amyloid-β plaques in a dose-dependent manner, according to interim results of a Phase 1b clinical trial.